Lantheus (NASDAQ:LNTH) Price Target Raised to $141.00

Lantheus (NASDAQ:LNTH) had its price objective hoisted by Truist Financial from $96.00 to $141.00 in a report issued on Thursday, Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other analysts have also recently commented on LNTH. Mizuho boosted their target price on shares of Lantheus from $90.00 to $100.00 and gave the company a buy rating in a report on Friday, May 3rd. JMP Securities upped their price target on shares of Lantheus from $100.00 to $130.00 and gave the stock an outperform rating in a research note on Wednesday. B. Riley upped their price target on shares of Lantheus from $95.00 to $99.00 and gave the stock a buy rating in a research note on Thursday, April 18th. SVB Leerink upped their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an outperform rating in a research note on Thursday. Finally, StockNews.com cut shares of Lantheus from a buy rating to a hold rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Lantheus presently has an average rating of Moderate Buy and a consensus price target of $113.86.

Lantheus Stock Performance

NASDAQ:LNTH opened at $123.42 on Thursday. The stock has a market cap of $8.55 billion, a P/E ratio of 18.84 and a beta of 0.51. The firm’s fifty day simple moving average is $81.97 and its 200 day simple moving average is $67.84. Lantheus has a twelve month low of $50.20 and a twelve month high of $124.90. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.11. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The firm had revenue of $369.98 million for the quarter, compared to analysts’ expectations of $349.46 million. As a group, research analysts predict that Lantheus will post 6.46 EPS for the current year.

Insiders Place Their Bets

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the sale, the chief accounting officer now owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel Niedzwiecki sold 12,873 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the sale, the insider now directly owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 44,799 shares of company stock valued at $3,748,151. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after acquiring an additional 100 shares during the period. Moody National Bank Trust Division grew its stake in shares of Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after acquiring an additional 162 shares during the period. Shaker Investments LLC OH grew its stake in shares of Lantheus by 0.7% during the 1st quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock valued at $1,740,000 after acquiring an additional 182 shares during the period. NBC Securities Inc. grew its stake in shares of Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 191 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 208 shares during the period. 99.06% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.